JPWO2022079290A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022079290A5
JPWO2022079290A5 JP2023547753A JP2023547753A JPWO2022079290A5 JP WO2022079290 A5 JPWO2022079290 A5 JP WO2022079290A5 JP 2023547753 A JP2023547753 A JP 2023547753A JP 2023547753 A JP2023547753 A JP 2023547753A JP WO2022079290 A5 JPWO2022079290 A5 JP WO2022079290A5
Authority
JP
Japan
Prior art keywords
cancer
compound
optionally substituted
none
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547753A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545588A (ja
JP7850460B2 (ja
JP2023545588A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/078696 external-priority patent/WO2022079290A2/en
Publication of JP2023545588A publication Critical patent/JP2023545588A/ja
Publication of JPWO2022079290A5 publication Critical patent/JPWO2022079290A5/ja
Publication of JP2023545588A5 publication Critical patent/JP2023545588A5/ja
Application granted granted Critical
Publication of JP7850460B2 publication Critical patent/JP7850460B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023547753A 2020-10-16 2021-10-15 ヘテロ環式カリンringユビキチンリガーゼ化合物及びその使用 Active JP7850460B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20202417.0 2020-10-16
EP20202417 2020-10-16
PCT/EP2021/078696 WO2022079290A2 (en) 2020-10-16 2021-10-15 Cullin ring ubiquitin ligase compounds and uses thereof

Publications (4)

Publication Number Publication Date
JP2023545588A JP2023545588A (ja) 2023-10-30
JPWO2022079290A5 true JPWO2022079290A5 (https=) 2024-11-08
JP2023545588A5 JP2023545588A5 (https=) 2024-11-08
JP7850460B2 JP7850460B2 (ja) 2026-04-23

Family

ID=72964476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547753A Active JP7850460B2 (ja) 2020-10-16 2021-10-15 ヘテロ環式カリンringユビキチンリガーゼ化合物及びその使用

Country Status (7)

Country Link
US (1) US20240132485A1 (https=)
EP (1) EP4229037A2 (https=)
JP (1) JP7850460B2 (https=)
CN (1) CN116568671A (https=)
AU (1) AU2021359129A1 (https=)
CA (1) CA3194868A1 (https=)
WO (1) WO2022079290A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023203174A1 (en) 2022-04-20 2023-10-26 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
CN116003424B (zh) * 2022-11-30 2024-03-19 中国药科大学 Shp2与mek1双靶点抑制剂及其制备方法与应用
JP2026501188A (ja) * 2022-12-16 2026-01-14 杭州阿諾生物医薬科技有限公司 サイクリンk分解剤及びその使用
WO2025040546A1 (en) * 2023-08-18 2025-02-27 Proxygen Gmbh Pyrazole compounds as cullin ring ubiquitin ligase compounds
WO2025104236A1 (en) * 2023-11-15 2025-05-22 Proxygen Gmbh Pyrazole compounds as cullin ring ubiquitin ligase compounds
CN119707806B (zh) * 2024-12-24 2025-12-12 河南师范大学 可见光催化不对称反应制备手性2-氮杂芳烃酰胺的方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4452901A (en) 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3483949D1 (de) 1983-09-26 1991-02-21 Udo Dr Med Ehrenfeld Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
CN1169520C (zh) 1997-09-29 2004-10-06 耐科塔医药公司 多孔微粒及其使用方法
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
CZ302070B6 (cs) 1998-04-21 2010-09-29 Micromet Ag Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
KR20020060160A (ko) * 1999-08-12 2002-07-16 파마시아 이탈리아 에스.피.에이. 3(5)-아미노-피라졸 유도체, 이의 제조 방법 및항종양제로서의 이의 용도
WO2001038309A1 (en) * 1999-11-24 2001-05-31 Cor Therapeutics, Inc. β-AMINO ACID-, ASPARTIC ACID- AND DIAMINOPROPIONIC-BASED INHIBITORS OF FACTOR Xa
ES2525087T5 (es) 2000-05-10 2018-06-28 Novartis Ag Polvos basados en fosfolípidos para administración de fármacos
PY0117895A (es) * 2000-07-31 2003-11-03 Pfizer Prod Inc Derivados de imidazol
IL154016A0 (en) * 2000-08-31 2003-07-31 Pfizer Prod Inc Pyrazole derivatives and their use as protein kinase inhibitors
EP1256578B1 (en) * 2001-05-11 2006-01-11 Pfizer Products Inc. Thiazole derivatives and their use as cdk inhibitors
JP2005514393A (ja) 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
AU2007312165A1 (en) * 2006-10-21 2008-04-24 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
JP4616237B2 (ja) 2006-11-07 2011-01-19 日本電信電話株式会社 シリコン化合物薄膜の形成方法
WO2008061796A2 (en) * 2006-11-24 2008-05-29 Ac Immune Sa Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
EP2309855A4 (en) * 2008-07-30 2012-06-27 Oncotherapy Science Inc BENZIMIDAZOLE DERIVATIVES AND GLYCOGEN SYNTHASE KINASE-3-BETA INHIBITORS CONTAINING THE SAME
CA2806766C (en) * 2010-07-28 2017-01-10 Neugen Pharma Inc. Novel amino imidazole compounds selectively suppress oxidative stress induced neurodegeneration
GB2513403A (en) * 2013-04-26 2014-10-29 Agency Science Tech & Res WNT pathway modulators
EP2878339A1 (en) * 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
CA2934700A1 (en) * 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Glutaminase inhibitors
JP6195684B2 (ja) * 2014-06-03 2017-09-13 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd ピラゾール化合物及びt型カルシウムチャンネルブロッカーとしてのそれらの使用
GB2533421A (en) * 2014-12-19 2016-06-22 Nordic Semiconductor Asa Integrated circuits
US10202376B2 (en) * 2014-12-24 2019-02-12 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN104447733B (zh) * 2015-01-05 2016-08-17 中国药科大学 1-苄基-2-吡咯啉酮-4-酰胺类化合物及其制备方法与应用
GB201501870D0 (en) * 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
JP2020503363A (ja) * 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド チューブリン結合化合物およびその治療的使用
EP3638664A1 (en) * 2017-06-14 2020-04-22 European Molecular Biology Laboratory Benzofuran amides and heteroaromatic analogues thereof for use in therapy
WO2019046668A1 (en) * 2017-08-31 2019-03-07 Kezar Life Sciences AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN
WO2019152437A1 (en) * 2018-01-30 2019-08-08 Foghorn Therapeutics Inc. Compounds and uses thereof
ES3032327T3 (en) * 2019-01-29 2025-07-17 Foghorn Therapeutics Inc Compounds and uses thereof
CN113330000B (zh) * 2019-01-31 2024-12-24 辉瑞公司 具有对cdk2的抑制活性的3-羰基氨基-5-环戊基-1fi-吡咯化合物

Similar Documents

Publication Publication Date Title
CN113614080A (zh) Kras g12c抑制剂化合物及其用途
JP2023123854A5 (https=)
JP2025024130A5 (https=)
JP2016513660A5 (https=)
JP2014517017A5 (ja) 化合物、その医薬組成物、及び癌治療用の阻害薬としてのその使用
JP2020517616A5 (https=)
JP2010539095A5 (https=)
HRP20160625T1 (hr) Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
GB2131428A (en) Amine derivatives having histamine h2-blocking activity
JP2015504076A5 (https=)
JP2021514395A5 (https=)
JP2020063289A5 (https=)
JPWO2022079290A5 (https=)
WO2002094261A1 (fr) Medicaments antagonistes de cxcr4 comprenant un compose contenant de l'azote
JP2013502441A5 (https=)
JPWO2021055295A5 (https=)
JP2021523169A5 (https=)
CN111511745A (zh) 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用
JP2009504771A5 (https=)
JPWO2019213445A5 (https=)
JP2007503432A5 (https=)
JP2024112835A5 (https=)
JP2016532714A5 (https=)
JP2005531563A5 (https=)
JPWO2019213570A5 (https=)